# Leyden Laboratories

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/leyden-laboratories-b-v

- Industry: Biotechnology
- Headquarters: Leiden, Netherlands
- Website: www.leydenlabs.com/
- Total disclosed funding: $187M
- Latest round: Series B (Jan 25, 2022)
- Investors on record: 7

## About

Founded in 2020, and headquartered in Leiden, Netherlands, Leyden Laboratories specializes in developing innovative healthcare solutions focused on infectious diseases, particularly through advanced vaccine candidates aimed at enhancing immunity. It focuses on healthcare innovations targeting infectious diseases and immunology. The company was co-founded by Dinko Valerio, Koenraad Wiedhaup, and Ronald Brus, with Koenraad Wiedhaup serving as CEO. In June 2026, Leyden Laboratories B.V. raised EUR 40 million from Gates Foundation Trust, European Innovation Council, Invest-NL, and ClavystBio. Leyden Laboratories specializes in innovative healthcare solutions focused on infectious diseases and immunology. Their core product offerings include advanced vaccine candidates designed to provide robust immunity against various pathogens, leveraging proprietary technology to enhance efficacy and safety profiles. These products are targeted at healthcare providers, government health agencies, and pharmaceutical companies, addressing the global need for effective vaccination strategies across North America, Europe, and parts of Asia.In 2023, Leyden Laboratories reported an EBITDA of USD -48,846,310.60. The company generates revenue through strategic partnerships and collaborations with stakeholders in the healthcare sector, including government entities and private healthcare providers. Their business model encompasses contractual agreements that facilitate the development and distribution of vaccine products, with revenue stemming from milestone payments and potential royalties upon market entry. The company will use the June 2026 funding to advance its programs through clinical development and support global access to respiratory virus protection solutions.

## Funding rounds

- Series B, Jan 25, 2022, $140M — Invus [DUP], F-Prime Capital, GV, Casdin Capital, SB Investment Advisers, BlueBird Ventures, Byers Capital
- Series A, Mar 25, 2021, $47M — F-Prime Capital, GV, Casdin Capital

## Investors

- F-Prime Capital (https://capitalatlas.ai/funds/f-prime-capital) — Series A, Series B
- GV (https://capitalatlas.ai/funds/gv) — Series A, Series B
- Casdin Capital (https://capitalatlas.ai/funds/casdin-capital) — Series A, Series B
- Invus [DUP] — Series B
- SB Investment Advisers (https://capitalatlas.ai/funds/sb-investment-advisers) — Series B
- BlueBird Ventures (https://capitalatlas.ai/funds/bluebird-ventures) — Series B
- Byers Capital (https://capitalatlas.ai/funds/byers-capital) — Series B